Lincoln Pharmaceuticals Limited (LINCOLN.NS)
INR 873.9
(1.21%)
INR 873.9
(1.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7 Billion INR | 19.21% |
| 2022 | 5.87 Billion INR | 9.93% |
| 2021 | 5.34 Billion INR | 16.32% |
| 2020 | 4.59 Billion INR | 25.52% |
| 2019 | 3.65 Billion INR | 0.2% |
| 2018 | 3.65 Billion INR | 5.19% |
| 2017 | 3.47 Billion INR | 13.17% |
| 2016 | 3.06 Billion INR | 11.97% |
| 2015 | 2.74 Billion INR | 6.2% |
| 2014 | 2.58 Billion INR | -0.37% |
| 2013 | 2.58 Billion INR | 8.42% |
| 2012 | 2.38 Billion INR | 11.01% |
| 2011 | 2.15 Billion INR | 33.85% |
| 2010 | 1.6 Billion INR | 44.92% |
| 2009 | 1.1 Billion INR | 51.9% |
| 2008 | 730.29 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 7 Billion INR | 19.21% |
| 2023 Q4 | 7 Billion INR | 0.0% |
| 2023 Q2 | 6.63 Billion INR | 0.0% |
| 2022 Q4 | 5.87 Billion INR | 0.0% |
| 2022 FY | 5.87 Billion INR | 9.93% |
| 2022 Q2 | 6.03 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 5.34 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 5.34 Billion INR | 16.32% |
| 2021 Q2 | 5.25 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 4.59 Billion INR | 25.52% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 4.59 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 4.47 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 4.19 Billion INR | 0.0% |
| 2019 Q4 | 3.65 Billion INR | 0.0% |
| 2019 FY | 3.65 Billion INR | 0.2% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 3.73 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 3.65 Billion INR | 5.19% |
| 2018 Q4 | 3.65 Billion INR | 0.0% |
| 2017 FY | 3.47 Billion INR | 13.17% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 3.47 Billion INR | 0.0% |
| 2017 Q2 | 3.35 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 3.06 Billion INR | 11.97% |
| 2016 Q4 | 3.06 Billion INR | 0.0% |
| 2016 Q2 | 2.91 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 FY | 2.74 Billion INR | 6.2% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 2.68 Billion INR | 0.0% |
| 2015 Q4 | 2.74 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 2.58 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 2.58 Billion INR | -0.37% |
| 2014 Q2 | 2.82 Billion INR | 0.0% |
| 2013 FY | 2.58 Billion INR | 8.42% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 2.58 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 2.38 Billion INR | 0.0% |
| 2012 Q4 | 2.38 Billion INR | 0.0% |
| 2012 Q2 | 2.2 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 FY | 2.38 Billion INR | 11.01% |
| 2011 Q4 | 2.15 Billion INR | 0.0% |
| 2011 FY | 2.15 Billion INR | 33.85% |
| 2010 FY | 1.6 Billion INR | 44.92% |
| 2009 FY | 1.1 Billion INR | 51.9% |
| 2008 FY | 730.29 Million INR | 0.0% |
| 2008 Q4 | 730.29 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | -0.884% |
| Ind-Swift Limited | 6.54 Billion INR | -7.001% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 8.474% |
| Sakar Healthcare Limited | 3.88 Billion INR | -80.181% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 98.446% |
| Innova Captab Limited | 13.2 Billion INR | 46.983% |
| Divi's Laboratories Limited | 154.7 Billion INR | 95.473% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 35.04% |
| Morepen Laboratories Limited | 12.93 Billion INR | 45.848% |
| Mankind Pharma Limited | 119.63 Billion INR | 94.146% |
| Sequent Scientific Limited | 15.4 Billion INR | 54.538% |
| Wanbury Limited | 3.43 Billion INR | -103.873% |
| Laurus Labs Limited | 83.87 Billion INR | 91.65% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 68.039% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 75.432% |
| Alembic Limited | 23.28 Billion INR | 69.929% |
| Hikal Limited | 24.87 Billion INR | 71.844% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 89.135% |
| Neuland Laboratories Limited | 18.32 Billion INR | 61.786% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 82.467% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 95.123% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 68.798% |
| Themis Medicare Limited | 5.66 Billion INR | -23.635% |
| RPG Life Sciences Limited | 5.12 Billion INR | -36.543% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 97.608% |
| Lupin Limited | 239.97 Billion INR | 97.082% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -90.882% |
| Wockhardt Limited | 76.49 Billion INR | 90.845% |
| Vaishali Pharma Limited | 799.55 Million INR | -775.848% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 72.879% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -222.599% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 93.936% |
| FDC Limited | 24.68 Billion INR | 71.626% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 98.193% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -191.713% |
| Eris Lifesciences Limited | 70.48 Billion INR | 90.065% |
| Venus Remedies Limited | 6.26 Billion INR | -11.719% |
| ZIM Laboratories Limited | 4.46 Billion INR | -56.727% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 42.309% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -589.187% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 74.038% |
| Shilpa Medicare Limited | 30.93 Billion INR | 77.36% |
| Albert David Limited | 4.97 Billion INR | -40.623% |
| Ajanta Pharma Limited | 46.38 Billion INR | 84.902% |
| Hester Biosciences Limited | 6.62 Billion INR | -5.729% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 68.932% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 70.157% |
| Gufic Biosciences Limited | 10.92 Billion INR | 35.903% |
| Windlas Biotech Limited | 6.26 Billion INR | -11.831% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 11.842% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -129.609% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -110.03% |
| Granules India Limited | 55.2 Billion INR | 87.316% |
| Aarti Drugs Limited | 24.32 Billion INR | 71.209% |
| Bal Pharma Limited | 3.2 Billion INR | -118.575% |
| Alkem Laboratories Limited | 155.74 Billion INR | 95.504% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.181% |
| Medicamen Biotech Limited | 2.94 Billion INR | -137.772% |
| Unichem Laboratories Limited | 31.69 Billion INR | 77.904% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -374.189% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -1387.362% |
| Valiant Laboratories Limited | 3.42 Billion INR | -104.353% |
| Orchid Pharma Limited | 15.53 Billion INR | 54.933% |
| Medico Remedies Limited | 961.95 Million INR | -627.988% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 39.895% |
| Ipca Laboratories Limited | 111.01 Billion INR | 93.692% |
| Brooks Laboratories Limited | 904.45 Million INR | -674.269% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -73.055% |
| Piramal Enterprises Limited | 826.05 Billion INR | 99.152% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 95.35% |
| NATCO Pharma Limited | 69.06 Billion INR | 89.86% |
| Suven Life Sciences Limited | 2.84 Billion INR | -145.8% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -293.036% |
| Strides Pharma Science Limited | 58.39 Billion INR | 88.008% |
| Indoco Remedies Limited | 21.44 Billion INR | 67.348% |
| Alpa Laboratories Limited | 1.82 Billion INR | -283.465% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -364.172% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -35.968% |